Our Pricing

Mounjaro vs Ozempic: UK Price Comparison and Clinical Efficacy Guide

Published on: June 03, 2026

When considering a mounjaro vs ozempic uk price comparison, understanding both cost and clinical outcomes is essential for making an informed choice. At Cured Pharmacy, we offer transparent pricing on both medications—Mounjaro from £124.99 and Wegovy (the weight loss formulation of the same active ingredient as Ozempic)—alongside expert guidance from our UK-registered clinical team to help you select the most appropriate treatment.

Understanding Mounjaro and Ozempic: How They Work

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. This dual mechanism activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure compared to single-pathway treatments.

Ozempic contains semaglutide, a selective GLP-1 receptor agonist originally licensed for type 2 diabetes management [2]. While Ozempic itself is indicated for diabetes, the same active ingredient is available as Wegovy at higher doses specifically licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities.

Both medications slow gastric emptying and reduce appetite by acting on hypothalamic centres that regulate hunger and satiety. However, tirzepatide's additional GIP agonism appears to provide superior weight reduction outcomes in head-to-head clinical trials, with patients achieving greater average body weight reductions over comparable timeframes [3].

Mounjaro vs Ozempic Clinical Trial Results

The SURPASS-2 trial directly compared tirzepatide (Mounjaro) against semaglutide 1mg in adults with type 2 diabetes, demonstrating that all three tirzepatide doses (5mg, 10mg, and 15mg) produced significantly greater reductions in HbA1c and body weight than semaglutide [3]. Patients receiving tirzepatide 15mg achieved an average body weight reduction of 11.2kg compared to 5.7kg with semaglutide 1mg over 40 weeks.

In the STEP trials evaluating semaglutide for weight management, participants receiving semaglutide 2.4mg (the Wegovy dose) achieved an average weight loss of 14.9% of initial body weight over 68 weeks [2]. The SURMOUNT-1 trial examining tirzepatide for weight management showed even more substantial results, with patients on the 15mg maintenance dose losing an average of 22.5% of their body weight over 72 weeks [1].

These trial outcomes suggest that whilst both medications produce clinically meaningful weight reduction when combined with lifestyle modifications, tirzepatide may offer superior efficacy for patients who are suitable candidates and can tolerate the higher doses. However, individual response varies, and your UK prescriber will assess which treatment aligns best with your medical history and weight management goals.

Real-World Efficacy Considerations

Clinical trial results represent controlled conditions with high adherence rates and structured support programmes. Real-world effectiveness depends on consistent medication use, dietary modifications, increased physical activity, and ongoing medical supervision. Both tirzepatide and semaglutide require gradual dose escalation to minimise gastrointestinal side effects, and not all patients tolerate or respond equally to maximum doses.

Side Effects: What to Expect with Mounjaro vs Ozempic

Both medications share similar side effect profiles due to their GLP-1 receptor agonist activity. The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort [1][2]. These symptoms typically emerge during dose escalation and often diminish as your body adapts to the medication over several weeks.

In clinical trials, gastrointestinal side effects occurred slightly more frequently with tirzepatide than with semaglutide, likely due to the dual receptor mechanism [3]. However, the gradual dose titration schedule recommended for both medications helps minimise these effects. Starting at lower doses and increasing slowly allows most patients to reach therapeutic levels with manageable symptoms.

Less common but serious risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not confirmed in humans). Both medications carry warnings about these risks, and patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use either treatment. Your prescriber will screen for contraindications during your clinical assessment.

Managing Side Effects Effectively

Most patients find gastrointestinal symptoms improve by eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and timing injections consistently. If side effects persist or worsen, your prescriber may adjust your dose escalation schedule or consider alternative treatments. Never increase your dose faster than prescribed, as this significantly increases the risk of intolerable side effects.

Mounjaro vs Ozempic UK Pricing and Value

At Cured Pharmacy, Mounjaro is available from £124.99 per pen, with pricing varying by prescribed dose strength following your clinical consultation. We offer transparent upfront pricing—you'll see the exact cost before completing your assessment, with no hidden fees or surprise charges at checkout.

Wegovy, which contains the same active ingredient as Ozempic at weight management doses, starts from £135.00 at Cured Pharmacy. Whilst the per-pen price differs between tirzepatide and semaglutide formulations, the overall value depends on treatment duration, dose requirements, and individual efficacy. Some patients achieve their weight management goals more quickly with tirzepatide, potentially reducing total treatment costs despite the higher per-pen price.

All prescription weight loss medications at Cured Pharmacy include a free online consultation with our UK-registered prescribers, discreet packaging, and reliable delivery. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all dispensing to ensure you receive genuine UK-licensed medications that meet MHRA standards. We guarantee the lowest prices in the UK—if you find a lower price elsewhere for the same medication and dose, we'll match it.

Who Should Choose Mounjaro vs Ozempic (Wegovy)?

Mounjaro is typically prescribed for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia [1]. Wegovy shares similar licensing criteria for weight management in the UK. Both require commitment to a reduced-calorie diet and increased physical activity as part of a comprehensive weight management programme.

Patients who have previously used semaglutide-based treatments with suboptimal results may be suitable candidates for switching to tirzepatide, subject to prescriber assessment. Conversely, those seeking a lower starting price point or who have successfully managed weight with semaglutide in the past may prefer to continue with Wegovy. Your medical history, current medications, contraindications, and treatment goals all influence which option is most appropriate.

Certain conditions preclude the use of both medications, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic ketoacidosis. Pregnant or breastfeeding women should not use either treatment. Our UK prescribers conduct thorough assessments during your online consultation to identify any contraindications and ensure safe prescribing.

Switching Between Treatments

If you're currently using one medication and considering switching to the other, discuss this with your prescriber rather than making changes independently. Transitioning between GLP-1 receptor agonists requires careful planning to minimise side effects and maintain treatment efficacy. Your prescriber will advise on appropriate washout periods, starting doses, and monitoring requirements when switching treatments.

How to Start Treatment at Cured Pharmacy

Beginning your weight loss journey with Mounjaro or Wegovy at Cured Pharmacy takes under three minutes. Start by completing our free online consultation, which asks about your medical history, current medications, weight management goals, and any contraindications. This assessment is reviewed by a UK-registered prescriber who determines whether treatment is safe and appropriate for you.

If approved, your prescription is sent directly to our dispensing team. We source all medications from licensed UK wholesalers and manufacturers, ensuring you receive genuine products that meet MHRA standards. Your treatment is dispatched in 100% discreet packaging with no external markings indicating the contents, protecting your privacy throughout the process.

Once you receive your medication, you'll find detailed instructions for injection technique, dose escalation, and storage requirements. Most patients administer injections once weekly on the same day each week, rotating injection sites between the abdomen, thigh, or upper arm. Our pharmacist-led support team is available on (+44) 116 4646009 if you have questions about your treatment or experience any concerns during therapy.

Ongoing Support and Monitoring

Weight management with injectable medications requires ongoing monitoring and support. We recommend regular follow-ups with your prescriber to assess treatment response, adjust doses as needed, and monitor for any adverse effects. Successful long-term weight management combines medication with sustainable dietary changes, regular physical activity, and behavioural modifications that support lasting lifestyle change.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Mounjaro and Wegovy are prescription-only medicines that must be used under medical supervision as part of a comprehensive weight management programme including diet and exercise. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Side effects can occur—read the patient information leaflet carefully and report any concerns to your prescriber.